{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:55:01Z","timestamp":1793202901198,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019349","name":"Nanjing Medical Science and Technique Development Foundation","doi-asserted-by":"publisher","award":["YKK21067"],"award-info":[{"award-number":["YKK21067"]}],"id":[{"id":"10.13039\/501100019349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019349","name":"Nanjing Medical Science and Technique Development Foundation","doi-asserted-by":"publisher","award":["JQX21002"],"award-info":[{"award-number":["JQX21002"]}],"id":[{"id":"10.13039\/501100019349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University","award":["2021-LCYJ-PY-43"],"award-info":[{"award-number":["2021-LCYJ-PY-43"]}]},{"name":"Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University","award":["2022-LCYJ-MS-07"],"award-info":[{"award-number":["2022-LCYJ-MS-07"]}]},{"name":"National Natural Science Fund","award":["82300719"],"award-info":[{"award-number":["82300719"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20211004"],"award-info":[{"award-number":["BK20211004"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02515-7","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T22:01:37Z","timestamp":1727560897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B"],"prefix":"10.1186","volume":"21","author":[{"given":"Fei","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanwu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"9963","key":"2515_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"regional Global","year":"2015","unstructured":"Global regional. National age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the global burden of Disease Study 2013. Lancet. 2015;385(9963):117\u201371.","journal-title":"Lancet"},{"issue":"24","key":"2515_CR2","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","volume":"337","author":"WM Lee","year":"1997","unstructured":"Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733\u201345.","journal-title":"N Engl J Med"},{"key":"2515_CR3","unstructured":"WHO. Guidelines for the diagnosis, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240090903 (accessed April 16, 2024)."},{"issue":"10381","key":"2515_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF, Hepatitis B. Lancet. 2023;401(10381):1039\u201352.","journal-title":"Lancet"},{"issue":"2","key":"2515_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"4","key":"2515_CR6","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"issue":"5","key":"2515_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"AM Hall","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2515_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","volume":"35","author":"L Mateo","year":"2016","unstructured":"Mateo L, Holgado S, Mari\u00f1oso ML, et al. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol. 2016;35(5):1271\u20139.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2515_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.13659","volume":"44","author":"P Lampertico","year":"2016","unstructured":"Lampertico P, Chan HLY, Janssen HLA, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44(1):16\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2515_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/apt.17107","volume":"56","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nakamuta M, Koyanagi T, et al. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther. 2022;56(4):713\u201322.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2515_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","volume":"20","author":"KS Byun","year":"2022","unstructured":"Byun KS, Choi J, Kim JH, et al. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: a Randomized Trial for switching from Tenofovir Disoproxil Fumarate. Clin Gastroenterol Hepatol. 2022;20(2):427\u2013e4375.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2515_CR12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, et al. Long-term treatment with Tenofovir Alafenamide for Chronic Hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119(3):486\u201396.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2515_CR13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/jac\/dkq464","volume":"66","author":"M Fabbiani","year":"2011","unstructured":"Fabbiani M, Bracciale L, Doino M, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother. 2011;66(3):682\u20133.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2515_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2515_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2515_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672\u201381.","journal-title":"J Hepatol"},{"key":"2515_CR17","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.2147\/DDDT.S274307","volume":"14","author":"N Squillace","year":"2020","unstructured":"Squillace N, Ricci E, Menzaghi B, et al. The Effect of switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on liver enzymes, glucose, and lipid Profile. Drug Des Devel Ther. 2020;14:5515\u201320.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2515_CR18","doi-asserted-by":"publisher","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","volume":"9","author":"PWG Mallon","year":"2022","unstructured":"Mallon PWG, Brunet L, Fusco JS, et al. Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL Cholesterol and triglycerides. Open Forum Infect Dis. 2022;9(1):ofab621.","journal-title":"Open Forum Infect Dis"},{"issue":"19","key":"2515_CR19","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection","year":"2001","unstructured":"Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486\u201397.","journal-title":"JAMA"},{"issue":"1","key":"2515_CR20","doi-asserted-by":"publisher","first-page":"10478","DOI":"10.1038\/s41598-022-14729-2","volume":"12","author":"S Pengpid","year":"2022","unstructured":"Pengpid S, Peltzer K. National high prevalence, and low awareness, treatment and control of dyslipidaemia among people aged 15\u201369 years in Mongolia in 2019. Sci Rep. 2022;12(1):10478.","journal-title":"Sci Rep"},{"issue":"8","key":"2515_CR21","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","volume":"20","author":"P Martin","year":"2022","unstructured":"Martin P, Nguyen MH, Dieterich DT, et al. Treatment algorithm for managing chronic Hepatitis B Virus infection in the United States: 2021 update. Clin Gastroenterol Hepatol. 2022;20(8):1766\u201375.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"2515_CR22","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/hep4.1964","volume":"6","author":"CQ Pan","year":"2022","unstructured":"Pan CQ, Afdhal NH, Ankoma-Sey V, et al. First-line therapies for hepatitis B in the United States: a 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun. 2022;6(8):1881\u201394.","journal-title":"Hepatol Commun"},{"key":"2515_CR23","first-page":"204993612098595","volume":"8","author":"L Roade","year":"2021","unstructured":"Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8:2049936120985954.","journal-title":"Ther Adv Infect Dis"},{"issue":"11","key":"2515_CR24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781\u20134.","journal-title":"AIDS"},{"issue":"11","key":"2515_CR25","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1002\/jmv.27977","volume":"94","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Liang J, Yin J, et al. Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients. J Med Virol. 2022;94(11):5465\u201374.","journal-title":"J Med Virol"},{"issue":"3","key":"2515_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403\u20138.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2515_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/apt.17765","volume":"59","author":"PN Cheng","year":"2024","unstructured":"Cheng PN, Feng IC, Chen JJ, et al. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2024;59(2):230\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"2515_CR28","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4254\/wjh.v15.i8.964","volume":"15","author":"RM Lai","year":"2023","unstructured":"Lai RM, Lin S, Wang MM, et al. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol. 2023;15(8):964\u201372.","journal-title":"World J Hepatol"},{"issue":"2","key":"2515_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3350\/cmh.2021.0314","volume":"28","author":"J Jeong","year":"2022","unstructured":"Jeong J, Shin JW, Jung SW, Park EJ, Park NH. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin Mol Hepatol. 2022;28(2):254\u201364.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"2515_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/apt.17764","volume":"59","author":"SK Fung","year":"2024","unstructured":"Fung SK, Pan CQ, Wong GLH, et al. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks. Aliment Pharmacol Ther. 2024;59(2):217\u201329.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2515_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"AA Shaheen","year":"2017","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46(6):599\u2013604.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2515_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3350\/cmh.2023.0328","volume":"30","author":"H Hong","year":"2024","unstructured":"Hong H, Choi WM, Lee D, et al. Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide. Clin Mol Hepatol. 2024;30(1):49\u201363.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2515_CR33","doi-asserted-by":"publisher","first-page":"e0261760","DOI":"10.1371\/journal.pone.0261760","volume":"17","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Suda G, Yamamoto Y, et al. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS ONE. 2022;17(1):e0261760.","journal-title":"PLoS ONE"},{"key":"2515_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63\u201370.","journal-title":"Antiviral Res"},{"issue":"9","key":"2515_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","volume":"43","author":"BP Kearney","year":"2004","unstructured":"Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595\u2013612.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2515_CR36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","volume":"67","author":"K Murata","year":"2018","unstructured":"Murata K, Asano M, Matsumoto A, et al. Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut. 2018;67(2):362\u201371.","journal-title":"Gut"},{"issue":"2","key":"2515_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","volume":"56","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Suda G, Yamamoto Y, et al. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56(2):168\u201380.","journal-title":"J Gastroenterol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02515-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02515-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02515-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T21:09:35Z","timestamp":1732828175000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02515-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02515-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Review Board of Nanjing Drum Tower Hospital (IRB number: 2008022) and was performed according to the ethical guidelines of the Declaration of Helsinki. A waiver of informed consent was approved by the ethics committee due to a retrospective design and deidentified data. This study has been registered under ClinicalTrials.gov (NCT03097952).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"234"}}